News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,277 Results
Type
Article (39614)
Company Profile (247)
Press Release (657416)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204124)
Career Advice (2007)
Deals (35413)
Drug Delivery (95)
Drug Development (81027)
Employer Resources (172)
FDA (16166)
Job Trends (14850)
News (345107)
Policy (32519)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2553)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49401)
ALS (86)
Alzheimer's disease (1367)
Antibody-drug conjugate (ADC) (112)
Approvals (16166)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (262)
Cancer (2080)
Cardiovascular disease (166)
Career advice (1674)
Career pathing (29)
CAR-T (143)
Cell therapy (402)
Cervical cancer (19)
Clinical research (65833)
Collaboration (792)
Compensation (505)
Complete response letters (19)
COVID-19 (2582)
CRISPR (37)
C-suite (223)
Cystic fibrosis (100)
Data (2047)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (256)
Diagnostics (6348)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86335)
Editorial (34)
Employer branding (21)
Employer resources (146)
Events (111885)
Executive appointments (692)
FDA (17347)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (717)
Gene editing (100)
Generative AI (19)
Gene therapy (284)
GLP-1 (697)
Government (4402)
Grass and pollen (4)
Guidances (51)
Healthcare (18811)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (26)
Infectious disease (2722)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (311)
IPO (16494)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (36)
Layoffs (459)
Leadership (16)
Legal (7905)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (280)
MASH (62)
Medical device (13342)
Medtech (13347)
Mergers & acquisitions (19434)
Metabolic disorders (655)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1872)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2530)
Now hiring (38)
Obesity (353)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (146)
Partnered (21)
Patents (221)
Patient recruitment (99)
Peanut (46)
People (57203)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20504)
Phase II (28987)
Phase III (21606)
Pipeline (1115)
Policy (127)
Postmarket research (2563)
Preclinical (8674)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (370)
Real estate (5906)
Recruiting (65)
Regulatory (22196)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2179)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (23)
The Weekly (28)
United States (21979)
Vaccines (665)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Today (106)
Last 7 days (497)
Last 30 days (2474)
Last 365 days (32978)
2025 (9175)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37749)
Australia (6176)
California (5773)
Canada (1937)
China (488)
Colorado (252)
Connecticut (262)
Delaware (134)
Europe (81014)
Florida (859)
Georgia (202)
Idaho (57)
Illinois (512)
India (25)
Indiana (299)
Iowa (9)
Japan (148)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (856)
Massachusetts (4328)
Michigan (215)
Minnesota (378)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1658)
New Mexico (28)
New York (1648)
North Carolina (935)
North Dakota (7)
Northern California (2530)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1302)
Puerto Rico (11)
Rhode Island (30)
South America (1096)
South Carolina (19)
South Dakota (1)
Southern California (2179)
Tennessee (99)
Texas (859)
Utah (171)
Virginia (135)
Washington D.C. (59)
Washington State (530)
West Virginia (3)
Wisconsin (51)
697,277 Results for "apollomics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
April 1, 2025
·
7 min read
Press Releases
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
April 4, 2025
·
11 min read
Biotech Bay
Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Inc. announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
May 29, 2024
·
1 min read
Business
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
March 4, 2024
·
5 min read
Business
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.
April 5, 2024
·
2 min read
Business
Apollomics Announces Private Placement Financing and Addition to Board of Directors
Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that it entered into subscription agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses.
May 8, 2024
·
5 min read
Biotech Bay
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics Inc. announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
March 28, 2024
·
12 min read
Biotech Bay
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.
February 7, 2024
·
4 min read
Business
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets.
March 26, 2024
·
4 min read
Drug Development
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics Inc., a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually.
June 4, 2024
·
7 min read
1 of 69,728
Next
